Perioperative Management of Rivaroxaban in Total Knee Arthroplasty

Preoperative Discontinuation

In patients with normal renal function undergoing total knee arthroplasty, rivaroxaban should be stopped 48 hours (≈2 days) before surgery—equivalent to about four drug half‑lives—resulting in only ~6 % residual anticoagulant effect at the time of incision. 1
The 48‑hour hold corresponds to skipping the dose that would have been taken the day before surgery; the last dose is therefore administered approximately 48 hours prior to the procedure. 1
For patients with renal impairment, the pre‑operative interruption should be extended to 72 hours (≈3 days) to achieve comparable drug clearance. [2][3]
No bridging with heparin is required during this brief interruption for routine atrial fibrillation patients; bridging is reserved for those with very high thrombotic risk. [2][3]

Rivaroxaban should be restarted on postoperative day 1 (POD 1) at dinner time (≈24–36 hours after surgery) using a reduced‑dose regimen (10 mg once daily) for the first two days, followed by the full therapeutic dose (20 mg once daily) thereafter. This stepwise approach balances bleeding risk with thromboprophylaxis. 1
Full therapeutic dosing (20 mg daily) should not be initiated until at least 24–72 hours post‑operatively, once adequate surgical hemostasis has been confirmed. [2][3]

Total knee arthroplasty is classified as a major, high‑bleeding‑risk orthopedic procedure; therefore postoperative anticoagulation must be timed to minimize bleeding while still protecting against thromboembolic events related to atrial fibrillation. [1][2]3
When prophylactic low‑molecular‑weight heparin (LMWH) is used immediately after surgery (e.g., 6 hours post‑op), a minimum 12‑hour interval should be observed before initiating therapeutic‑dose rivaroxaban to avoid overlapping anticoagulant effects. [2][3]

Resuming full‑dose rivaroxaban on POD 0 markedly increases bleeding risk without additional thrombotic protection and should be avoided. 1
Holding rivaroxaban for only one day pre‑operatively provides insufficient drug clearance (only ~2 half‑lives) for major orthopedic surgery and should not be practiced. 1
Extending the pre‑operative hold to three days in patients with normal renal function is unnecessary; it raises thrombotic risk without further bleeding benefit. [1][2]
Post‑operative monitoring of renal function is essential because acute kidney injury can impair rivaroxaban clearance and may necessitate dose adjustment. [2][3]